Press Releases – Sweden

December 11, 2017

Immune Pharmaceuticals Appoints John Zhang, MD, PhD as Vice President, Research and Development

Englewood Cliffs, NJ, USA – December 11, 2017 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has appointed John Zhang, MD, PhD to the position of Vice President, Research and Development. Dr. Zhang will […]

Keep Reading

November 27, 2017

Immune Provides Update Regarding NASDAQ US Listing and Departure of Officer

Englewood Cliffs, New Jersey, USA – November 27, 2017 – Immune Pharmaceuticals Inc. (the “Company”) announced today the public disclosure of certain information regarding its continued listing on NASDAQ US and the departure of its VP Finance. Notice of Compliance with NASDAQ US Listing Rule On August 23, 2017, the Company received a letter from […]

Keep Reading

November 17, 2017

Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

Englewood Cliffs, NJ – November 15, 2017 – Immune Pharmaceuticals Inc. (Nasdaq First North: IMNP) (“Immune”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the quarter ending September 30, 2017 and provided a corporate update. Third Quarter 2017 and Recent Highlights On October […]

Keep Reading